Linked Life Data

17266629

Source:http://linkedlifedata.com/resource/pubmed/id/17266629

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-2-1
pubmed:abstractText
Moexipril is a long-acting, non-sulfhydryl angiotensine-converting enzyme inhibitor. It is used for treatment of arterial hypertension. Moexipril is the prodrug, yielding moexiprilat by hydrolysis of an ethyl ester group. Moexiprilat is the metabolite responsible for the pharmacological effect after moexipril administration. Samples of rat and human microsomal preparations exposed to moexipril treatment were analyzed by HPLC using octyl silica stationary phase and isocratic elution. To detect moexipril and moexiprilat the separation was monitored by both ultraviolet and mass specific detection. The rat liver microsomal preparation was more effective to in producing moexiprilat than the similar one derived from human liver cell lines. While additional potential metabolites of moexipril were suggested by computer-modeling, moexiprilat was the sole metabolite detected after microsomal treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1573-4064
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
101-6
pubmed:dateRevised
2008-2-26
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS.
pubmed:affiliation
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. Huba.kalasz@gmail.com
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't